Artiva Biotherapeutics, Inc.

ARTV

Healthcare Biotechnology

Artiva Biotherapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $251,000.00, down 99.3% from fiscal 2023.

EPS
+27.6%
Free cash flow
+13.6%

Quarter to June 2026, against a year earlier

4.15 0.02 +0.48%
Market cap
$202.9M
P/E
n/m
Fwd P/E
n/m
Dividend yield
—
F-score
n/a
ROIC
0.00%
Net debt / EBITDA
1.2×
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

— — — —
EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
11.65 8.61 8.16 24.16
Net Debt/EBITDA
5.53 5.08 3.65 13.34
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.81) (0.62) (0.86) (0.53)
Book value per Share
5.28 4.50 3.56 8.82
Free Cash Flow
(19.80) (15.15) (21.19) (20.77)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates · fundamentals updated 26 Oct 2026